CRISPR Therapeutics
CRISPR Therapeutics raises $337M Follow-on Offering at $8B valuation
CRISPR Therapeutics: Follow-on Offering Funding Round
CRISPR Therapeutics has successfully raised $337M in Follow-on Offering funding, reaching a valuation of $8B.
Company Overview
Gene-based medicines using CRISPR/Cas9
Funding Details
The Follow-on Offering round was led by Versant Ventures, with participation from Bayer, Vertex Pharmaceuticals.
Company Information
- Headquarters: Aeschenvorstadt 36, Basel 4051, Switzerland
- Founded: 2013
- Employees: 500+
- Category: Biotech
Investment
CRISPR Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Versant Ventures: Verified investor in Follow-on Offering
- Bayer: Verified investor in Follow-on Offering
- Vertex Pharmaceuticals: Verified investor in Follow-on Offering
Company Info
Investors (3)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free